Literature DB >> 18179166

Serological immunoreactivity against colon cancer proteome varies upon disease progression.

Lucia De Monte1, Francesca Sanvito, Stefano Olivieri, Fiammetta Viganò, Claudio Doglioni, Matteo Frasson, Marco Braga, Angela Bachi, Paolo Dellabona, Maria Pia Protti, Massimo Alessio.   

Abstract

Sera from colon carcinoma patients were used to identify tumor-associated antigens (TAAs) by screening tumor proteome resolved by 2D electrophoresis. A panel of six TAAs eliciting a serological immune response in colorectal cancer was identified, showing a modification in antigen recognition by B cells in patients as a function of colon cancer progression. The expression of these proteins was either confined or increased in tumor as compared to normal mucosa.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18179166     DOI： 10.1021/pr070360m

Source DB:  PubMed          Journal:  J Proteome Res        ISSN： 1535-3893            Impact factor:   4.466


  8 in total

1.  Proteome-based analysis of serologically defined tumor-associated antigens in cutaneous lymphoma.

Authors:  Michael Forgber; Sylke Gellrich; Tumenjargal Sharav; Wolfram Sterry; Peter Walden
Journal:  PLoS One       Date:  2009-12-18       Impact factor: 3.240

2.  Differential influence of anticancer treatments and angiogenesis on the seric titer of autoantibody used as tumor and metastasis biomarker.

Authors:  Florence Defresne; Caroline Bouzin; Céline Guilbaud; Marc Dieu; Edouard Delaive; Carine Michiels; Martine Raes; Olivier Feron
Journal:  Neoplasia       Date:  2010-07       Impact factor: 5.715

3.  Immunoscreening of the extracellular proteome of colorectal cancer cells.

Authors:  Susanne Klein-Scory; Salwa Kübler; Hanna Diehl; Christina Eilert-Micus; Anke Reinacher-Schick; Kai Stühler; Bettina Warscheid; Helmut E Meyer; Wolff Schmiegel; Irmgard Schwarte-Waldhoff
Journal:  BMC Cancer       Date:  2010-02-25       Impact factor: 4.430

4.  Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer.

Authors:  Lucia De Monte; Michele Reni; Elena Tassi; Daniela Clavenna; Ilenia Papa; Helios Recalde; Marco Braga; Valerio Di Carlo; Claudio Doglioni; Maria Pia Protti
Journal:  J Exp Med       Date:  2011-02-21       Impact factor: 14.307

5.  An Optimized Fluorescence-Based Bidimensional Immunoproteomic Approach for Accurate Screening of Autoantibodies.

Authors:  Virginie Dutoit-Lefèvre; Sylvain Dubucquoi; David Launay; Vincent Sobanski; Patricia Dussart; Philippe Chafey; Cédric Broussard; Sophie Duban-Deweer; Patrick Vermersch; Lionel Prin; Didier Lefranc
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

6.  A possible role of transglutaminase 2 in the nucleus of INS-1E and of cells of human pancreatic islets.

Authors:  Sara Sileno; Valentina D'Oria; Riccardo Stucchi; Massimo Alessio; Stefania Petrini; Valentina Bonetto; Pierre Maechler; Federico Bertuzzi; Valeria Grasso; Katia Paolella; Fabrizio Barbetti; Ornella Massa
Journal:  J Proteomics       Date:  2013-11-27       Impact factor: 4.044

7.  Proteome serological determination of tumor-associated antigens in melanoma.

Authors:  Michael Forgber; Uwe Trefzer; Wolfram Sterry; Peter Walden
Journal:  PLoS One       Date:  2009-04-17       Impact factor: 3.240

8.  Serological immune response against ADAM10 pro-domain is associated with favourable prognosis in stage III colorectal cancer patients.

Authors:  Sheila María Álvarez-Fernández; Marco Barbariga; Luca Cannizzaro; Carlo Vittorio Cannistraci; Laura Hurley; Alan Zanardi; Antonio Conti; Francesca Sanvito; Anna Innocenzi; Nicolò Pecorelli; Marco Braga; Massimo Alessio
Journal:  Oncotarget       Date:  2016-11-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.